Navigation Links
CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
Date:6/4/2008

TORONTO, June 4 /PRNewswire/ -- The 12-month results from a multicenter trial monitoring CellCept(R) (mycophenolate mofetil) in combination with calcineurin inhibitors (CNIs) in renal transplantation was presented today at the American Transplant Congress (ATC). The study results showed that a reduced level of CNI with a therapeutic monitored dose of CellCept is not inferior to that of a fixed dose of CellCept, and the standard-dose of CNI as it relates to biopsy-proven acute rejection (BPAR) and other end points.

The lower CNI dose regimen studied to avoid long-term side effects of chronic administration of CNI, facilitated a higher CellCept dosing without an overall increase in adverse events, and with a trend toward preservation of kidney function versus the standard-dose CNI regimens. As transplant patients are living longer, studies suggest that therapies such as CNIs can cause impairment of kidney function, damage to the blood vessels, and filtering capacity of the kidneys.

"The Opticept trial was designed to examine the impact of monitored CellCept dosing to enable a low dose CNI regimen with fewer complications and preservation of efficacy in preventing rejection," said Robert Gaston, M.D., lead investigator, University of Alabama at Birmingham, Birmingham, AL. "The 12-month study results are very encouraging and additional follow-up may provide insights into the long-term impact of these short-term findings."

About the Study

Opticept is a two-year open-label, prospective, randomized, multicenter study involving 720 single-organ renal allograft recipients administered either concentration-controlled CellCept and a reduced level of CNI, a concentration-controlled CellCept and the standard level of CNI, or a fixed-dose of CellCept and the standard level CNI.

Antibody induction and/or corticosteroids were administered according to center practice. Primary endpoints were the proportion of patients with treatment failure
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
2. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
3. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
4. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
5. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
6. Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
7. Reduced Lung Capacity Accelerates With Diabetes
8. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Breast Cancer Treatment Is Reduced to One Week
11. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  Kastle Therapeutics (Kastle), a biopharmaceutical company ... diseases with high unmet medical needs, announced today ... commercial operating positions. Sean McAuliffe ... was previously Global Marketing Director for Baxalta. ... Commercial Strategy and Analytics; Nick was previously Director, ...
(Date:9/2/2015)... -- Ascletis announced today the completion of a US$35 ... by C-Bridge Capital, joined by Tasly Pharmaceutical and ... the Company before financing was US$300 million. ... expand Ascletis, pipeline, strengthen global development capabilities and enhance ... the investors, Ascletis is now entering an exciting new ...
(Date:9/2/2015)... SARASOTA, Fla. , Sept. 2, 2015   ... announced a new capital infusion of $17 million by ... of Cerner Corporation, and Bedford Funding. Series D funding ... Voalte has raised to nearly $60 million in three ... to sustain a triple-digit growth trajectory for Voalte. The ...
Breaking Medicine Technology:Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3Ascletis Secures US$35 Million Financing 2Ascletis Secures US$35 Million Financing 3Voalte Raises $17 Million in Series D Financing 2Voalte Raises $17 Million in Series D Financing 3Voalte Raises $17 Million in Series D Financing 4
... FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medical,professionals seeking ... of,hospital-acquired gram-negative pneumonia may have a new ... being,developed by Nektar Therapeutics (Nasdaq:NKTR)., Results of ... use of,NKTR-061 (Inhaled Amikacin) to treat mechanically ...
... MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--May,21, ... CXSP) notes,the publication of new clinical data ... The paper "Targeted,therapy and the T315I mutation ... colleagues at the University of,Bologna, Italy (Haematologica ...
Cached Medicine Technology:Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
(Date:9/2/2015)... ... 2015 , ... Density measurement is used in many labs ... makes density measurements more efficient and error-free. The new METTLER TOLEDO video compares ... the advantages compared to manual sample handling. , The Evolution of Density Measurement ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... food banks in commemorating “Hunger Action Month” during the entire month of September. ... Food Bank will be dedicating its efforts this September to an awareness campaign ...
(Date:9/2/2015)... ... September 02, 2015 , ... A third party administrator ... after seeing a significant increase in unlawful tactics used by out-of-network (OON) ambulatory ... cases of OON ASCs encouraging members to have elective procedures done at their ...
(Date:9/2/2015)... Chicago, IL (PRWEB) , ... September 02, 2015 ... ... engineer of patented products, announces Hand Free Pocket Cop, a safety invention that ... in the US is worth $31 billion," says Scott Cooper, CEO and Creative ...
(Date:9/2/2015)... ... 2015 , ... On September 9, 2015, over 27,000 people from all over ... convention to date for the state of Utah. , “We are thrilled with the ... David Stirling, doTERRA CEO. “One of the most exciting elements of our convention is ...
Breaking Medicine News(10 mins):Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2
... A North Carolina team of doctors, nurses, hospitals and ... way to provide faster, more effective treatment for heart ... or fancy new equipment. But it does require competitors ... to move treatment forward empowering emergency services personnel ...
... condition, which is symptomless, can lead to heart attack ... More American women are suffering from asymptomatic peripheral artery ... risk for heart attack and stroke, a new study ... of an increase in common cardiovascular risk factors, namely ...
... from union benefit funds,Union coalition says Rite Aid wants union money, but ... ... They are telling conference attendees: Trust Rite Aid? Think Twice!, ... pharmacy benefits management company (Rite Aid,Solutions) at the International Foundation Employee Benefits ...
... TARRYTOWN, N.Y., Nov. 3 EpiCept Corporation,(Nasdaq and OMX ... a,conference call to discuss third quarter 2007 results and ... 8:30 a.m. EST. EpiCept,will release results for the three ... EST on Monday, November 5, 2007. (Logo: ...
... is disappointed with today,s ruling and we intend to ... at issue was the result of,highly competitive conditions in ... ruling on liability is thus profoundly,anti- competitive. AstraZeneca ... drugs and we firmly believe that we have acted ...
... Mexican Red Cross for Flood,Relief, WASHINGTON, Nov. 2 ... to provide $50,000 to the Mexican Red Cross to,assist ... than,800,000 people. Unusually heavy rains caused rivers to overflow ... was already waterlogged,after Hurricanes Dean and Felix., "Thousands ...
Cached Medicine News:Health News:RACE: a statewide model of better, faster heart attack care 2Health News:RACE: a statewide model of better, faster heart attack care 3Health News:Peripheral Artery Disease Up Sharply Among U.S. Women 2Health News:Peripheral Artery Disease Up Sharply Among U.S. Women 3Health News:Rite Aid's Fledgling Benefits Management Firm Hits Turbulence at Employee Benefits Conference in Anaheim 2Health News:EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007 2Health News:EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007 3Health News:Sister Red Cross Societies Help Each Other 2
... contemporary reading card was designed by James ... of near point exercises including words, numbers ... 20/260, 20/200, 20/100, 20/65, 20/50, 20/40, 20/30, ... reading in English and metric, Jaeger, point ...
Standard reading test. "walked regularly..."...
Standard reading test. "Children should be..."...
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
Medicine Products: